ClinicalTrials.Veeva

Menu

TLN-499 in Combination With Venetoclax in Patients With Relapsed/Refractory Solid Tumors

T

Treeline Biosciences, Inc.

Status and phase

Enrolling
Phase 1

Conditions

Small Cell Lung Cancer ( SCLC )
Malignant Pleural Mesotheliomas (Mpm)
Neuroendocrine Cancer
Synovial Sarcomas

Treatments

Drug: TLN-499
Drug: Venetoclax

Study type

Interventional

Funder types

Industry

Identifiers

NCT07713732
TLN-499-2601

Details and patient eligibility

About

The purpose of this first-in-human study is to evaluate the safety, tolerability, pharmacokinetics, and preliminary antitumor activity of TLN-499 in combination with venetoclax in participants with relapsed/refractory solid tumors.

Enrollment

120 estimated patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  1. Adults ≥18 years of age
  2. Histologically confirmed relapsed/refractory SCLC, neuroendocrine cancer, malignant pleural mesothelioma, or synovial sarcoma
  3. Measurable disease per RECIST v1.1 or mRECIST
  4. ECOG performance status 0-1
  5. Adequate hematologic, hepatic, renal, and coagulation function.
  6. Life expectancy ≥12 weeks
  7. Signed informed consent

Exclusion criteria

  1. Active brain metastases
  2. Major surgery or severe trauma within 4 weeks before first dose
  3. Significant uncontrolled medical conditions preventing study participation
  4. Use of prohibited concomitant medications
  5. Previous conditions that would interfere with study assessments or safety

Trial design

Primary purpose

Treatment

Allocation

N/A

Interventional model

Single Group Assignment

Masking

None (Open label)

120 participants in 1 patient group

Part 1 Dose Escalation and Part 2 Dose Expansion
Experimental group
Treatment:
Drug: Venetoclax
Drug: TLN-499

Trial contacts and locations

3

Loading...

Central trial contact

Treeline Clinical Operations

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems